Now showing items 1-8 of 8

    • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. 

      Dunning, AM; Michailidou, K; Kuchenbaecker, KB; Thompson, D; French, JD; Beesley, J; Healey, CS; Kar, S; Pooley, KA; Lopez-Knowles, E; Dicks, E; Barrowdale, D; Sinnott-Armstrong, NA; Sallari, RC; Hillman, KM; Kaufmann, S; Sivakumaran, H; Moradi Marjaneh, M; Lee, JS; Hills, M; Jarosz, M; Drury, S; Canisius, S; Bolla, MK; Dennis, J; Wang, Q; Hopper, JL; Southey, MC; Broeks, A; Schmidt, MK; Lophatananon, A; Muir, K; Beckmann, MW; Fasching, PA; Dos-Santos-Silva, I; Peto, J; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; González-Neira, A; Perez, JIA; Anton-Culver, H; Eunjung, L; Arndt, V; Brenner, H; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Aittomäki, K; Blomqvist, C; Ito, H; Matsuo, K; Bogdanova, N; Dörk, T; Lindblom, A; Margolin, S; Kosma, V-M; Mannermaa, A; Tseng, C-C; Wu, AH; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Peterlongo, P; Radice, P; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Goldberg, MS; Teo, SH; Yip, CH; Nord, S; Borresen-Dale, A-L; Kristensen, V; Long, J; Zheng, W; Pylkäs, K; Winqvist, R; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; Figueroa, J; Sherman, ME; Czene, K; Darabi, H; Hollestelle, A; van den Ouweland, AMW; Humphreys, K; Gao, Y-T; Shu, X-O; Cox, A; Cross, SS; Blot, W; Cai, Q; Ghoussaini, M; Perkins, BJ; Shah, M; Choi, J-Y; Kang, D; Lee, SC; Hartman, M; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Brennan, P; Sangrajrang, S; Ambrosone, CB; Toland, AE; Shen, C-Y; Wu, P-E; Orr, N; Swerdlow, A; McGuffog, L; Healey, S; Lee, A; Kapuscinski, M; John, EM; Terry, MB; Daly, MB; Goldgar, DE; Buys, SS; Janavicius, R; Tihomirova, L; Tung, N; Dorfling, CM; van Rensburg, EJ; Neuhausen, SL; Ejlertsen, B; Hansen, TVO; Osorio, A; Benitez, J; Rando, R; Weitzel, JN; Bonanni, B; Peissel, B; Manoukian, S; Papi, L; Ottini, L; Konstantopoulou, I; Apostolou, P; Garber, J; Rashid, MU; Frost, D; EMBRACE; Izatt, L; Ellis, S; Godwin, AK; Arnold, N; Niederacher, D; Rhiem, K; Bogdanova-Markov, N; Sagne, C; Stoppa-Lyonnet, D; Damiola, F; GEMO Study Collaborators; Sinilnikova, OM; Mazoyer, S; Isaacs, C; Claes, KBM; De Leeneer, K; de la Hoya, M; Caldes, T; Nevanlinna, H; Khan, S; Mensenkamp, AR; HEBON; Hooning, MJ; Rookus, MA; Kwong, A; Olah, E; Diez, O; Brunet, J; Pujana, MA; Gronwald, J; Huzarski, T; Barkardottir, RB; Laframboise, R; Soucy, P; Montagna, M; Agata, S; Teixeira, MR; kConFab Investigators; Park, SK; Lindor, N; Couch, FJ; Tischkowitz, M; Foretova, L; Vijai, J; Offit, K; Singer, CF; Rappaport, C; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Imyanitov, EN; Hulick, PJ; Phillips, K-A; Piedmonte, M; Mulligan, AM; Glendon, G; Bojesen, A; Thomassen, M; Caligo, MA; Yoon, S-Y; Friedman, E; Laitman, Y; Borg, A; von Wachenfeldt, A; Ehrencrona, H; Rantala, J; Olopade, OI; Ganz, PA; Nussbaum, RL; Gayther, SA; Nathanson, KL; Domchek, SM; Arun, BK; Mitchell, G; Karlan, BY; Lester, J; Maskarinec, G; Woolcott, C; Scott, C; Stone, J; Apicella, C; Tamimi, R; Luben, R; Khaw, K-T; Helland, Å; Haakensen, V; Dowsett, M; Pharoah, PDP; Simard, J; Hall, P; García-Closas, M; Vachon, C; Chenevix-Trench, G; Antoniou, AC; Easton, DF; Edwards, SL (2016-04)
      We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor α) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each ...
    • Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. 

      López-Knowles, E; Gao, Q; Cheang, MCU; Morden, J; Parker, J; Martin, L-A; Pinhel, I; McNeill, F; Hills, M; Detre, S; Afentakis, M; Zabaglo, L; Dodson, A; Skene, A; Holcombe, C; Robertson, J; Smith, I; Bliss, JM; Dowsett, M; POETIC trialists (2016-04)
      <h4>Background</h4>Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect ...
    • Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. 

      Cuzick, J; Brentnall, AR; Segal, C; Byers, H; Reuter, C; Detre, S; Lopez-Knowles, E; Sestak, I; Howell, A; Powles, TJ; Newman, WG; Dowsett, M (2017-03)
      Purpose At least 94 common single nucleotide polymorphisms (SNPs) are associated with breast cancer. The extent to which an SNP panel can refine risk in women who receive preventive therapy has not been directly assessed ...
    • Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. 

      Gellert, P; Segal, CV; Gao, Q; López-Knowles, E; Martin, L-A; Dodson, A; Li, T; Miller, CA; Lu, C; Mardis, ER; Gillman, A; Morden, J; Graf, M; Sidhu, K; Evans, A; Shere, M; Holcombe, C; McIntosh, SA; Bundred, N; Skene, A; Maxwell, W; Robertson, J; Bliss, JM; Smith, I; Dowsett, M; POETIC Trial Management Group and Trialists (2016-11-09)
      Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I ...
    • Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. 

      Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, MK; Kingston, B; O'Leary, B; Herrera-Abreu, MT; Cutts, RJ; Garcia-Murillas, I; Bye, H; Walker, BA; Gonzalez De Castro, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, EF; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, AFC; Johnston, SRD; Ring, A; Turner, NC (2020-02)
      <h4>Purpose</h4>Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the ...
    • Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. 

      Gao, Q; López-Knowles, E; U Cheang, MC; Morden, J; Ribas, R; Sidhu, K; Evans, D; Martins, V; Dodson, A; Skene, A; Holcombe, C; Mallon, E; Evans, A; Bliss, JM; Robertson, J; Smith, I; Martin, L-A; Dowsett, M; POETIC Trial Management Group and Trialists (2018-04)
      To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery ...
    • Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. 

      Lopez-Knowles, E; Pearson, A; Schuster, G; Gellert, P; Ribas, R; Yeo, B; Cutts, R; Buus, R; Garcia-Murillas, I; Haynes, B; Martin, L-A; Smith, I; Turner, N; Dowsett, M (2019-01)
      BACKGROUND:Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS ...
    • β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. 

      Schade, B; Lesurf, R; Sanguin-Gendreau, V; Bui, T; Deblois, G; O'Toole, SA; Millar, EKA; Zardawi, SJ; Lopez-Knowles, E; Sutherland, RL; Giguère, V; Kahn, M; Hallett, M; Muller, WJ (2013-07)
      Although ERBB2 amplification and overexpression is correlated with poor outcome in breast cancer, the molecular mechanisms underlying the aggressive nature of these tumors has not been fully elucidated. To investigate this ...